

Treatment Naïve

Boceprevir in Treatment Naive SPRINT-2

Boceprevir for Treatment-Naïve HCV Genotype 1

SPRINT-2 Trial: Study Design

SPRINT-2: Study Features

- N = 1097 HCV-monoinfected patients (159 black)
- Randomized, double-blind, placebo-controlled, phase 3 study
- All with chronic HCV and genotype 1 and treatment naïve
- HCV RNA \geq 10,000 IU/ml
- Age \geq 18
- Setting: international sites
- Randomized to 3 arms (1:1:1)


Drug Dosing

Boceprevir = 800 mg three times daily

Peginterferon alfa-2b = 1.5 μ g/kg once weekly


Ribavirin = 600-1400 mg/day (based on weight)

Boceprevir for Treatment-Naïve HCV Genotype 1 SPRINT-2 Trial: Treatment Regimens



Boceprevir for Treatment-Naïve HCV Genotype 1 SPRINT-2 Trial: Treatment Regimens


SPRINT-2: SVR 24 by Regimen



B = Boceprevir; PR = Peginterferon + Ribavirin

Boceprevir for Treatment-Naïve HCV Genotype 1 SPRINT-2 Trial: Results

SPRINT-2: SVR 24 by Regimen




SVR = Sustained Virologic Response; B = Boceprevir; PR = Peginterferon + Ribavirin

Source: Poordad F, et al. *N Engl J Med.* 2011;364:1195-206.

Boceprevir for Treatment-Naïve HCV Genotype 1 SPRINT-2 Trial: SVR by Liver Histology

SPRINT-2: SVR 24 by Degree of Fibrosis



PR48 = Peginteron/Ribavirin x 48 weeks

SVR = Sustained Virologic Response; B = Boceprevir; PR = Peginterferon + Ribavirin

Source: Poordad F, et al. *N Engl J Med.* 2011;364:1195-206.

Boceprevir for Treatment-Naïve HCV Genotype 1 SPRINT-2 Trial: Conclusions

Conclusions: “The addition of boceprevir to standard therapy with peginterferon–ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir.”